Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis.

Tabata K, Katashima M, Kawamura A, Kagayama A, Kohno S.

Eur J Drug Metab Pharmacokinet. 2006 Apr-Jun;31(2):123-8.

PMID:
16898081
2.
3.

Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs.

Niwa T, Shiraga T, Ishii I, Kagayama A, Takagi A.

Biol Pharm Bull. 2005 Sep;28(9):1711-6.

4.

Interindividual variability in 5-Fluorouracil metabolism and procainamide N-acetylation in human liver cytosol.

Niwa T, Shiraga T, Ohno Y, Kagayama A.

Biol Pharm Bull. 2005 Jun;28(6):1071-4.

5.

Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population.

Iwasaki M, Yoshimura Y, Asahi S, Saito K, Sakai S, Morita S, Takenaka O, Inoda T, Kashiyama E, Aoyama A, Nakabayashi T, Omori S, Kuwabara T, Izumi T, Nakamura K, Takanaka K, Nakayama Y, Takeuchi M, Nakamura H, Kametani S, Terauchi Y, Hashizume T, Nagayama S, Kume T, Achira M, Kawai H, Kawashiro T, Nakamura A, Nakai Y, Kagayama A, Shiraga T, Niwa T, Yoshimura T, Morita J, Ohsawa F, Tani M, Osawa N, Ida K, Noguchi K.

Drug Metab Pharmacokinet. 2004 Dec;19(6):444-52.

6.

Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031.

Ishikawa T, Nishigaki F, Miyata S, Hirayama Y, Minoura K, Imanishi J, Neya M, Mizutani T, Imamura Y, Naritomi Y, Murai H, Ohkubo Y, Kagayama A, Mutoh S.

Br J Pharmacol. 2005 Jan;144(1):133-43.

7.
8.

New SRM data dependent exclusion (MS)n measurement for structural determination of drug metabolites using LC/ESI/Ion trap MS.

Tozuka Z, Kaneko H, Shiraga T, Beppu M, Niwa T, Kawamura A, Kagayama A.

Drug Metab Pharmacokinet. 2003;18(6):390-403.

9.

Evidence for singlet oxygen involvement in rat and human cytochrome P450-dependent substrate oxidations.

Yasui H, Deo K, Ogura Y, Yoshida H, Shiraga T, Kagayama A, Sakurai H.

Drug Metab Pharmacokinet. 2002;17(5):416-26.

10.

Strategy for structure elucidation of drug metabolites derived from protonated molecules and (MS)n fragmentation of zotepine, tiaramide and their metabolites.

Tozuka Z, Kaneko H, Shiraga T, Mitani Y, Kawamura A, Kagayama A, Aoba A.

Drug Metab Pharmacokinet. 2002;17(4):316-39.

11.
13.
14.

Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats.

Niwa T, Yokota Y, Tokunaga A, Yamato Y, Kagayama A, Fujiwara T, Hatakeyama J, Anezaki M, Ohtsuka Y, Takagi A.

Biol Pharm Bull. 2004 Jul;27(7):1154-6.

15.
16.

Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes.

Niwa T, Shiraga T, Hashimoto T, Kagayama A.

Biol Pharm Bull. 2004 Jan;27(1):97-9.

17.

Strategy for structural elucidation of drugs and drug metabolites using (MS)n fragmentation in an electrospray ion trap.

Tozuka Z, Kaneko H, Shiraga T, Mitani Y, Beppu M, Terashita S, Kawamura A, Kagayama A.

J Mass Spectrom. 2003 Aug;38(8):793-808. Review.

PMID:
12938100
18.

In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes.

Niwa T, Shiraga T, Yamasaki S, Ishibashi K, Ohno Y, Kagayama A.

Xenobiotica. 2003 Jul;33(7):717-29.

PMID:
12893521
19.

Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro.

Naritomi Y, Terashita S, Kagayama A, Sugiyama Y.

Drug Metab Dispos. 2003 May;31(5):580-8.

PMID:
12695346
20.

Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.

Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y.

Drug Metab Dispos. 2001 Oct;29(10):1316-24.

PMID:
11560875
21.

Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.

Niwa T, Shiraga T, Mitani Y, Terakawa M, Tokuma Y, Kagayama A.

Drug Metab Dispos. 2000 Sep;28(9):1128-34.

PMID:
10950860
22.

Residual short-range order in the heavy fermion compound CeInCu2.

Takahashi I I, Kagayama A, Oomi G, Onuki Y, Komatsubara T.

Acta Crystallogr B. 1999 Feb 1;55(Pt 1):31-34.

PMID:
10927336
23.

Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: synthesis and in vivo characterization of osteotropic carboxyfluorescein.

Fujisaki J, Tokunaga Y, Takahashi T, Hirose T, Shimojo F, Kagayama A, Hata T.

J Drug Target. 1995;3(4):273-82.

PMID:
8821001
24.

Oral absorption of FK506 in rats.

Kagayama A, Tanimoto S, Fujisaki J, Kaibara A, Ohara K, Iwasaki K, Hirano Y, Hata T.

Pharm Res. 1993 Oct;10(10):1446-50.

PMID:
7505939
25.

Liposomal sustained-release delivery systems for intravenous injection V. Biological disposition of liposome-entrapped lipophilic prodrug of 1-beta-D-arabinofuranosylcytosine.

Tokunaga Y, Iwasa T, Fujisaki J, Sawai S, Kagayama A.

Chem Pharm Bull (Tokyo). 1988 Oct;36(10):4060-7. No abstract available.

PMID:
3245983
26.

Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-beta-D-arabinofuranosylcytosine prodrug-bearing liposomes.

Tokunaga Y, Iwasa T, Fujisaki J, Sawai S, Kagayama A.

Chem Pharm Bull (Tokyo). 1988 Sep;36(9):3574-83. No abstract available.

PMID:
3240548
27.

Liposomal sustained-release delivery systems for intravenous injection. III. Antitumor activity of lipophilic mitomycin C prodrug-bearing liposomes.

Tokunaga Y, Iwasa T, Fujisaki J, Sawai S, Kagayama A.

Chem Pharm Bull (Tokyo). 1988 Sep;36(9):3565-73. No abstract available.

PMID:
3149215
28.

Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes.

Tokunaga Y, Iwasa T, Fujisaki J, Sawai S, Kagayama A.

Chem Pharm Bull (Tokyo). 1988 Sep;36(9):3557-64. No abstract available.

PMID:
3149214
29.

Liposomal sustained-release delivery systems for intravenous injection. I. Physicochemical and biological properties of newly synthesized lipophilic derivatives of mitomycin C.

Tokunaga Y, Iwasa T, Fujisaki J, Sawai S, Kagayama A.

Chem Pharm Bull (Tokyo). 1988 Aug;36(8):3060-9. No abstract available.

PMID:
3149212
30.

Effect of some ionic and nonionic surfactants on the intramuscular absorption of isonicotinamide.

Kobayashi H, Peng T, Kagayama A, Okumura K, Muranishi S.

Chem Pharm Bull (Tokyo). 1975 Jan;23(1):42-7. No abstract available.

PMID:
126119

Supplemental Content

Loading ...
Support Center